Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Infectious Diseases

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 1 · 25%High 1 · 25%

Adherence · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).

1 finding from 1 review

Hepatotoxicity · HIV‐negative people at risk of TB infection1

Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).

1 finding from 1 review

Active TB · HIV‐negative people at risk of TB infection1

It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).

1 finding from 1 review